Ron H J Mathijssen (Ron Hj Mathijssen)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 52

Top Topics

Metastatic Renal Cell Carcinoma

Positive Breast Cancer

Vascular Endothelial Growth Factor

Top Venues

CPT: pharmacometrics & systems pharmacology

Clinical pharmacology and therapeutics

Journal of the American Heart Association

This page only lists publications with an associated author ORCID identifier.

Publications

Spinel Karas, Ron H J Mathijssen, Ron H N van Schaik, Alan Forrest, Timothy Wiltshire, Robert R Bies, Federico Innocenti
Model-Based Prediction of Irinotecan-Induced Grade 4 Neutropenia in Cancer Patients: Influence of Incorporating Germline Genetic Factors in the Model. Clinical pharmacology and therapeutics 115 (5) (2024)
Anna M Mc Laughlin, Thomas Helland, Fenja Klima, Stijn L W Koolen, Ron H N van Schaik, Ron H J Mathijssen, Patrick Neven, Jesse Joachim Swen, Henk-Jan Guchelaar, Florence Dalenc, Melanie White-Koning, Robin Michelet, Gerd Mikus, Werner Schroth, Thomas Mürdter, Hiltrud B Brauch, Matthias Schwab, Håvard Søiland, Gunnar Mellgren, Fabienne Thomas, Charlotte Kloft, Daniel Louis Hertz, null null
Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort. Clinical pharmacology and therapeutics (2024)
Niels A D Guchelaar, Maud B A van der Kleij, Neeltje Steeghs, Alwin D R Huitema, Ron H J Mathijssen, Stijn L W Koolen
Therapeutic Drug Monitoring of Oral Oncology Drugs: Finding the Right Nails. Clinical pharmacology and therapeutics (2024)
Anyue Yin, G D Marijn Veerman, Johan G C van Hasselt, Christi M J Steendam, Hendrikus Jan Dubbink, Henk-Jan Guchelaar, Lena E Friberg, Anne-Marie C Dingemans, Ron H J Mathijssen, Dirk Jan A R Moes
Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib. CPT: pharmacometrics & systems pharmacology (2024)
Thomas Drabison, Mike Boeckman, Yan Yang, Kevin M Huang, Peter de Bruijn, Mahesh R Nepal, Josie A Silvaroli, Anika T Chowdhury, Eric D Eisenmann, Xiaolin Cheng, Navjot Singh Pabla, Ron H J Mathijssen, Sharyn D Baker, Shuiying Hu, Alex Sparreboom, Zahra Talebi
Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen. Cancer research communications (2024)
Pascale C S Rietveld, Sebastiaan D T Sassen, Niels A D Guchelaar, Ruben A G van Eerden, Nadine L de Boer, Teun B M van den Heuvel, Jacobus W A Burger, Ron H J Mathijssen, Birgit C P Koch, Stijn L W Koolen
Population pharmacokinetics of intraperitoneal irinotecan and SN-38 in patients with peritoneal metastases from colorectal origin. CPT: pharmacometrics & systems pharmacology 13 (6) (2024)
Niels A D Guchelaar, Maud B A van der Kleij, Neeltje Steeghs, Alwin D R Huitema, Ron H J Mathijssen, Stijn L W Koolen
Therapeutic Drug Monitoring of Oral Oncology Drugs: Finding the Right Nails. Clinical pharmacology and therapeutics 116 (3) (2024)
Maud B A van der Kleij, Niels A D Guchelaar, Marinda Meertens, Kim Westerdijk, Eline L Giraud, Roos F Bleckman, Stefanie L Groenland, Ruben A G van Eerden, Alex L T Imholz, Annelie J E Vulink, Hans-Martin Otten, Helle-Brit Fiebrich-Westra, Floor J E Lubberman, Ingrid M E Desar, Dirk Jan A R Moes, Daan J Touw, Stijn L W Koolen, Hans Gelderblom, Anna K L Reyners, Nielka P van Erp, Ron H J Mathijssen, Alwin D R Huitema, null null, Neeltje Steeghs
Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology - an analysis of the closed cohorts of a multicentre prospective study. British journal of cancer 131 (5) (2024)
Spinel Karas, Ron H J Mathijssen, Ron H N van Schaik, Alan Forrest, Timothy Wiltshire, Robert R Bies, Federico Innocenti
Model-Based Prediction of Irinotecan-Induced Grade 4 Neutropenia in Cancer Patients: Influence of Incorporating Germline Genetic Factors in the Model. Clinical pharmacology and therapeutics (2024)
Anyue Yin, G D Marijn Veerman, Johan G C van Hasselt, Christi M J Steendam, Hendrikus Jan Dubbink, Henk-Jan Guchelaar, Lena E Friberg, Anne-Marie C Dingemans, Ron H J Mathijssen, Dirk Jan A R Moes
Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Anyue Yin, G D Marijn Veerman, Johan G C van Hasselt, Christi M J Steendam, Hendrikus Jan Dubbink, Henk-Jan Guchelaar, Lena E Friberg, Anne-Marie C Dingemans, Ron H J Mathijssen, Dirk Jan A R Moes
Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Dirk Jan A R Moes, Jeroen J M A Hendrikx, Henk-Jan Guchelaar, Ron H J Mathijssen, J L Bakker, Vincent O Dezentjé, Nikki de Rouw, Nielka P van Erp, Egbert F Smit, Michel van den Heuvel, Thijs H Oude Munnink, Maartje van Kats, Sander Croes, Judith R Kroep, Juliette Zwaveling, Rob Ter Heine
Model-Informed Development of a Cost-Saving Dosing Regimen for Sacituzumab Govitecan. Targeted oncology (2024)
Anyue Yin, G D Marijn Veerman, Johan G C van Hasselt, Christi M J Steendam, Hendrikus Jan Dubbink, Henk-Jan Guchelaar, Lena E Friberg, Anne-Marie C Dingemans, Ron H J Mathijssen, Dirk Jan A R Moes
Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Anna M Mc Laughlin, Thomas Helland, Fenja Klima, Stijn L W Koolen, Ron H N van Schaik, Ron H J Mathijssen, Patrick Neven, Jesse Joachim Swen, Henk-Jan Guchelaar, Florence Dalenc, Melanie White-Koning, Robin Michelet, Gerd Mikus, Werner Schroth, Thomas Mürdter, Hiltrud B Brauch, Matthias Schwab, Håvard Søiland, Gunnar Mellgren, Fabienne Thomas, Charlotte Kloft, Daniel Louis Hertz, null null
Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort. Clinical pharmacology and therapeutics 116 (3) (2024)
Pascale C S Rietveld, Sebastiaan D T Sassen, Niels A D Guchelaar, Ruben A G van Eerden, Nadine L de Boer, Teun B M van den Heuvel, Jacobus W A Burger, Ron H J Mathijssen, Birgit C P Koch, Stijn L W Koolen
Population pharmacokinetics of intraperitoneal irinotecan and SN-38 in patients with peritoneal metastases from colorectal origin. CPT: pharmacometrics & systems pharmacology 13 (6) (2024)
Pascale C S Rietveld, Sebastiaan D T Sassen, Niels A D Guchelaar, Ruben A G van Eerden, Nadine L de Boer, Teun B M van den Heuvel, Jacobus W A Burger, Ron H J Mathijssen, Birgit C P Koch, Stijn L W Koolen
Population pharmacokinetics of intraperitoneal irinotecan and SN-38 in patients with peritoneal metastases from colorectal origin. CPT: pharmacometrics & systems pharmacology 13 (6) (2024)
Pascale C S Rietveld, Sebastiaan D T Sassen, Niels A D Guchelaar, Ruben A G van Eerden, Nadine L de Boer, Teun B M van den Heuvel, Jacobus W A Burger, Ron H J Mathijssen, Birgit C P Koch, Stijn L W Koolen
Population pharmacokinetics of intraperitoneal irinotecan and SN-38 in patients with peritoneal metastases from colorectal origin. CPT: pharmacometrics & systems pharmacology (2024)
Anyue Yin, G D Marijn Veerman, Johan G C van Hasselt, Christi M J Steendam, Hendrikus Jan Dubbink, Henk-Jan Guchelaar, Lena E Friberg, Anne-Marie C Dingemans, Ron H J Mathijssen, Dirk Jan A R Moes
Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Maud B A van der Kleij, Niels A D Guchelaar, Marinda Meertens, Kim Westerdijk, Eline L Giraud, Roos F Bleckman, Stefanie L Groenland, Ruben A G van Eerden, Alex L T Imholz, Annelie J E Vulink, Hans-Martin Otten, Helle-Brit Fiebrich-Westra, Floor J E Lubberman, Ingrid M E Desar, Dirk Jan A R Moes, Daan J Touw, Stijn L W Koolen, Hans Gelderblom, Anna K L Reyners, Nielka P van Erp, Ron H J Mathijssen, Alwin D R Huitema, null null, Neeltje Steeghs
Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology - an analysis of the closed cohorts of a multicentre prospective study. British journal of cancer (2024)
Anyue Yin, G D Marijn Veerman, Johan G C van Hasselt, Christi M J Steendam, Hendrikus Jan Dubbink, Henk-Jan Guchelaar, Lena E Friberg, Anne-Marie C Dingemans, Ron H J Mathijssen, Dirk Jan A R Moes
Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Spinel Karas, Ron H J Mathijssen, Ron H N van Schaik, Alan Forrest, Timothy Wiltshire, Robert R Bies, Federico Innocenti
Model-Based Prediction of Irinotecan-Induced Grade 4 Neutropenia in Cancer Patients: Influence of Incorporating Germline Genetic Factors in the Model. Clinical pharmacology and therapeutics 115 (5) (2024)
Sanne M Buijs, C Louwrens Braal, Stefan A J Buck, Noud F van Maanen, Lonneke M van der Meijden-Erkelens, Heleen A Kuijper-Tissot van Patot, Esther Oomen-de Hoop, Lotte Saes, Sophia J van den Boogerd, Liesbeth E M Struik, Quirine C van Rossum-Schornagel, Ron H J Mathijssen, Stijn L W Koolen, Agnes Jager
CBD-oil as a potential solution in case of severe tamoxifen-related side effects. NPJ breast cancer 9 (1) (2023)
Maud B A van der Kleij, Niels A D Guchelaar, Ron H J Mathijssen, Jurjen Versluis, Alwin D R Huitema, Stijn L W Koolen, Neeltje Steeghs
Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology. Clinical pharmacokinetics (2023)
Sofía Lj Peeters, Maarten J Deenen, Anna Mj Thijs, Emma C Hulshof, Ron H J Mathijssen, André B P van Kuilenburg, Henk-Jan Guchelaar, Jesse Joachim Swen
UGT1A1 genotype-guided dosing of irinotecan: time to prioritize patient safety. Pharmacogenomics (2023)
Karlijn de Joode, Sharon Veenbergen, Claudia Kransse, Dian Kortleve, Reno Debets, Ron H J Mathijssen, Arjen Joosse, Marco W J Schreurs, Astrid A M Van der Veldt
Suitability of tumor-associated antibodies as predictive biomarker for response to immune checkpoint inhibitors in patients with melanoma: a short report. Journal for immunotherapy of cancer 11 (2) (2023)
Jonathan E Knikman, Tycho A Wilting, Marta Lopez-Yurda, Linda M Henricks, Carin A T C Lunenburg, Femke M de Man, Didier M Meulendijks, Peter Nieboer, Helga J Droogendijk, Geert-Jan M Creemers, Caroline M P W Mandigers, Alexander L T Imholz, Ron H J Mathijssen, Johanneke E A Portielje, Liselot Valkenburg-van Iersel, Annelie Vulink, Marlene H W van der Poel, Arnold Baars, Jesse Joachim Swen, André B P van Kuilenburg, Jan H M Schellens, Jos H Beijnen, Henk-Jan Guchelaar, Annemieke Cats
Survival of Patients With Cancer With DPYD Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy-A Matched-Pair Analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Karlijn de Joode, Sharon Veenbergen, Claudia Kransse, Dian Kortleve, Reno Debets, Ron H J Mathijssen, Arjen Joosse, Marco W J Schreurs, Astrid A M Van der Veldt
Suitability of tumor-associated antibodies as predictive biomarker for response to immune checkpoint inhibitors in patients with melanoma: a short report. Journal for immunotherapy of cancer 11 (2) (2023)
Stefan A J Buck, Annelies Van Hemelryk, Corrina de Ridder, Debra Stuurman, Sigrun Erkens-Schulze, Sem Van 't Geloof, Wilma J Teubel, Stijn L W Koolen, Elena S Martens-Uzunova, Martin E van Royen, Ronald de Wit, Ron H J Mathijssen, Thomas A Kirkland
Darolutamide added to docetaxel augments antitumor effect in models of prostate cancer through cell cycle arrest at the G1-S transition. Molecular cancer therapeutics (2023)
Aurelius G Omlin, Richard Cathomas, Gunhild von Amsberg, Christoph Reuter, Susan Feyerabend, Wolfgang Loidl, Martin Boegemann, Anja Lorch, Axel Heidenreich, Igor Tsaur, Julian Larcher-Senn, Stefan A J Buck, Ron H J Mathijssen, Ulrich Jaehde, Silke Gillessen Sommer, Markus Joerger
Randomized phase 2 Cabazitaxel dose individualization and Neutropenia prevention Trial (CAINTA) in patients with metastatic castration-resistant prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Daan C H van Dorst, Sumeyye Kabadayi, Esther Oomen-de Hoop, Alexander H J Danser, Ron H J Mathijssen, Jorie Versmissen
Treatment and Implications of Vascular Endothelial Growth Factor Inhibitor-Induced Blood Pressure Rise: A Clinical Cohort Study. Journal of the American Heart Association 12 (1) (2022)
Daan C H van Dorst, Sumeyye Kabadayi, Esther Oomen-de Hoop, Alexander H J Danser, Ron H J Mathijssen, Jorie Versmissen
Treatment and Implications of Vascular Endothelial Growth Factor Inhibitor-Induced Blood Pressure Rise: A Clinical Cohort Study. Journal of the American Heart Association 12 (1) (2022)
Daan C H van Dorst, Sumeyye Kabadayi, Esther Oomen-de Hoop, Alexander H J Danser, Ron H J Mathijssen, Jorie Versmissen
Treatment and Implications of Vascular Endothelial Growth Factor Inhibitor-Induced Blood Pressure Rise: A Clinical Cohort Study. Journal of the American Heart Association 12 (1) (2022)
Yang Li, Yan Jin, Hanieh Taheri, Keith T Schmidt, Alice A Gibson, Stefan A J Buck, Eric D Eisenmann, Ron H J Mathijssen, William Douglas Figg, Sharyn D Baker, Alex Sparreboom, Shuiying Hu
A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug-Drug Interaction Liabilities. Pharmaceutics 14 (9) (2022)
Daan C H van Dorst, Sumeyye Kabadayi, Esther Oomen-de Hoop, Alexander H J Danser, Ron H J Mathijssen, Jorie Versmissen
Treatment and Implications of Vascular Endothelial Growth Factor Inhibitor-Induced Blood Pressure Rise: A Clinical Cohort Study. Journal of the American Heart Association 12 (1) (2022)
Meta H M Diekstra, Jesse Joachim Swen, Loes F M van der Zanden, Sita H Vermeulen, Epie Boven, Ron H J Mathijssen, Koya Fukunaga, Taisei Mushiroda, Fumiya Hongo, Egbert Oosterwijk, Anne Cambon-Thomsen, Daniel Castellano, Achim Fritsch, Jesus Garcia Donas, Cristina Rodriguez-Antona, Rob Ruijtenbeek, Marius T Radu, Tim Eisen, Kerstin Junker, Max Roessler, Ulrich Jaehde, Tsuneharu Miki, Stefan Böhringer, Michiaki Kubo, Lambertus A L M Kiemeney, Henk-Jan Guchelaar
Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib. Cancers 14 (12) (2022)
Mirjam de With, Gemma Brufau, Laila A van den Berg, Femke M de Man, Marija Trajkovic, Martine F Thijs, Rob Castel, Henricus J Vermeer, Samira El Bouazzaoui, Amber van Hemel, Maja Matic, Ron H J Mathijssen, Sander Bins, Ron H N van Schaik
DPYD*7 as a Predictor of Severe Fluoropyrimidine-Related Adverse Events. JCO precision oncology 6 (2022)
Daan C H van Dorst, Sumeyye Kabadayi, Esther Oomen-de Hoop, Alexander H J Danser, Ron H J Mathijssen, Jorie Versmissen
Treatment and Implications of Vascular Endothelial Growth Factor Inhibitor-Induced Blood Pressure Rise: A Clinical Cohort Study. Journal of the American Heart Association 12 (1) (2022)
Daan C H van Dorst, Sumeyye Kabadayi, Esther Oomen-de Hoop, Alexander H J Danser, Ron H J Mathijssen, Jorie Versmissen
Treatment and Implications of Vascular Endothelial Growth Factor Inhibitor-Induced Blood Pressure Rise: A Clinical Cohort Study. Journal of the American Heart Association (2022)
Mirjam de With, Jonathan E Knikman, Jan H M Schellens, André B P van Kuilenburg, Annemieke Cats, Henk-Jan Guchelaar, Ron H J Mathijssen, Jesse Joachim Swen, Didier Meulendijks
Response to "Plasma Uracil as a DPD Phenotyping Test: Pre-analytical Handling Matters". Clinical pharmacology and therapeutics (2022)
Leni van Doorn, Marie-Rose B S Crombag, Hánah N Rier, Jeroen L A van Vugt, Charlotte van Kesteren, Sander Bins, Ron H J Mathijssen, Mark-David Levin, Stijn L W Koolen
The Influence of Body Composition on the Systemic Exposure of Paclitaxel in Esophageal Cancer Patients. Pharmaceuticals (Basel, Switzerland) 14 (1) (2021)
Florence Atrafi, Ruben A G van Eerden, Stijn L W Koolen, Peter de Bruijn, Cristianne J F Rijcken, Rob Hanssen, Ferry A L M Eskens, Martijn P Lolkema, Esther Oomen-de Hoop, Jeffrey Damman, Ron H J Mathijssen
Docetaxel Skin Exposure and Micronucleation Contributes to Skin Toxicity Caused by CPC634. Cancers 13 (15) (2021)
Daniel P Hurkmans, Sebastiaan D T Sassen, Karlijn de Joode, Lisanne Putter, Edwin A Basak, Annemarie J M Wijkhuijs, Markus Joerger, Reno Debets, Birgit C P Koch, Cor H Van der Leest, Marco W J Schreurs, Astrid A M van der Veldt, Joachim G J V Aerts, Ron H J Mathijssen, Stijn L W Koolen
Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors. Journal for immunotherapy of cancer 9 (6) (2021)
Ruben A G van Eerden, Esther Oomen-de Hoop, Aad Noordam, Ron H J Mathijssen, Stijn L W Koolen
Feasibility of Extrapolating Randomly Taken Plasma Samples to Trough Levels for Therapeutic Drug Monitoring Purposes of Small Molecule Kinase Inhibitors. Pharmaceuticals (Basel, Switzerland) 14 (2) (2021)
Leni van Doorn, Mandy M van Rosmalen, Wendy M van der Deure, Esther Oomen-de Hoop, Robert Porrazzo, Sophie M Wijngaard, Ingrid A Boere, Paola Veenstra, Eman Ibrahim, Peter de Bruijn, Lena E Friberg, Stijn L W Koolen, Ron H J Mathijssen, Agnes Jager
Effect of Scalp Cooling on the Pharmacokinetics of Paclitaxel. Cancers 13 (15) (2021)
Tessa A M Mulder, Mirjam de With, Marzia Del Re, Romano Danesi, Ron H J Mathijssen, Ron H N van Schaik
Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy. Cancers 13 (4) (2021)
Koen G A M Hussaarts, Leni van Doorn, Sander Bins, Dave Sprengers, Peter de Bruijn, Roelof W F van Leeuwen, Stijn L W Koolen, Teun van Gelder, Ron H J Mathijssen
Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma. Pharmaceuticals (Basel, Switzerland) 14 (1) (2021)
Wesley S van de Geer, Youri Hoogstrate, Kaspar Draaisma, Pierre A Robe, Sander Bins, Ron H J Mathijssen, Pim J French, Harmen J G van de Werken, Filip Yves Francine De Vos
Landscape of driver gene events, biomarkers, and druggable targets identified by whole-genome sequencing of glioblastomas. Neuro-oncology advances 4 (1) (2021)
Mirjam de With, Daan P Hurkmans, Esther Oomen-de Hoop, Ayoub Lalouti, Sander Bins, Samira El Bouazzaoui, Mandy van Brakel, Reno Debets, Joachim G J V Aerts, Ron H N van Schaik, Ron H J Mathijssen, Astrid A M van der Veldt
Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy. Cancers 13 (6) (2021)
Stefanie L Groenland, Remy B Verheijen, Markus Joerger, Ron H J Mathijssen, Alex Sparreboom, Jos H Beijnen, Jan H Beumer, Neeltje Steeghs, Alwin D R Huitema
Precision Dosing of Targeted Therapies Is Ready for Prime Time. Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Bram C Agema, Astrid W Oosten, Sebastiaan D T Sassen, Wim J R Rietdijk, Carin C D van der Rijt, Birgit C P Koch, Ron H J Mathijssen, Stijn L W Koolen
Population Pharmacokinetics of Oxycodone and Metabolites in Patients with Cancer-Related Pain. Cancers 13 (11) (2021)
Florence Atrafi, Oliver Boix, Vivek Subbiah, Jennifer R Diamond, Sant P Chawla, Anthony W Tolcher, Patricia M LoRusso, Joseph P Eder, Martin Gutierrez, Kumar Sankhala, Prabhu Rajagopalan, Isabelle Genvresse, Simon Langer, Ron H J Mathijssen, Jaap Verweij, Ingmar Bruns, Martijn Paul Lolkema
A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (23) (2021)
Jip M van Elst, Nikki S IJzerman, Ron H J Mathijssen, Neeltje Steeghs, Anna K L Reyners, Jacco-Juri de Haan
Taste, smell and mouthfeel disturbances in patients with gastrointestinal stromal tumors treated with tyrosine-kinase inhibitors. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2021)